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The use of recombinant retroviral vectors to effect corrective genetic therapies in hematopoietic stem cells
(HSCs) has long been predicted to revolutionize medicine. Two recent papers in Science now show that this
technology could be considered as effective as, and perhaps superior to, allogeneic HSC transplants in some
rare diseases.Thirty years ago, retroviral transfer of
genetic material into hematopoietic stem
and progenitor cells (HSC/Ps) cells led
to predictions that this technology would
transform modern medicine (Joyner
et al., 1983; Williams et al., 1984). Since
the initial excitement surrounding these
early studies, the field has been hampered
by inefficient gene transfer into rare
HSC/P populations and a tarnished image
arising from insertional mutagenesis
caused by transfer vectors, resulting in
oncogene transactivation and leukemias.
Two recent studies in Science, from Ales-
sandra Biffi and Alessandro Aiuti (Aiuti
et al., 2013; Biffi et al., 2013) and col-
leagues, now report significant advances
toward improved gene transfer with third
generation lentivirus vectors, showing
both efficacy and early safety in treating
two severe genetic diseases.
Biffi et al. (2013) report gene transfer
into HSC/P cells from patients with the
lysosomal storage disease metachro-
matic leukodystrophy disease (MLD).
This is a genetic disease caused by defi-
ciency of arylsulfatase A (ARSA), resulting
in nerve demyelination. The disease
manifests with devastating, progressive
motor and cognitive impairment and
death within the first years of life. Results
of hematopoietic stem cell transplantation
(HSCT) have been variable and contro-
versial, with several confounding factors
including degree of chimerism, posttrans-
plant complications, and age and status
of the patients at the time of transplant.
Biffi et al. hypothesized that microglial
cells derived from gene modified HSC/
Ps would replace the resident micro-
glial population over time and provide
both local and systemic replacement ofthe nonfunctional endogenous protein.
Importantly in this case, the investigators
surmised that expression of the protein
at higher than normal levels (compared,
for instance, to a normal donor’s cells)
would increase efficacy. Thus, the investi-
gators optimized vector delivery via modi-
fied virus vector and cell manufacturing
methods to effect a higher rate of gene
transfer into HSCs than in previous trials.
Although these modifications increased
overall gene transfer efficiency, this
adjustment means that many cells will
have multiple independent integrations
of the vector in the genome, which also
increases the theoretical risk of insertional
mutagenesis.
The result was an impressive halt in the
disease progression in the first three
patients reported that were treated 2–
12 months before the age of onset of their
affected siblings. There were measura-
ble and objective improvements in brain
imaging, electrophysiological measure-
ments, biochemical studies, and disease
progression when compared to previous
affected siblings in each family. Vector
copy number (VCN) in various cell popula-
tions ranged between 2.5 and 4.4 VCN/
genome (as opposed to 1–2 in previous
studies), and up to 80% of cells in the
blood contained the vector sequences.
The integrated vector led to expression
of ARSA at >10-fold the levels in healthy
controls, and functional protein was found
in the cerebral spinal fluid at levels com-
parable to those in normal controls at 1
and 2 years postinfusion of genetically
modified HSC/Ps. Another study from
Aiuti et al. (2013) utilized a lentivirus vector
to effect gene transfer into HSC/Ps from
patients with Wiskott-Aldrich syndromeCell Stem Cell 13, S(WAS). Patients with WAS have defective
WAS protein, an effector of the small
GTPase CDC42 that regulates cytoskel-
etal function in blood cell lineages.
Patients suffer from immune deficiency
with recurrent infections, autoimmune
symptoms, and thrombocytopenia with
abnormally small and dysfunctional plate-
lets leading to excessive bleeding and an
increased risk of leukemia and lymphoma.
The study is noteworthy in part because a
previous trial in this disease using gene
transfer into HSC/Ps showed efficacy,
but multiple subjects developed leukemia
from insertional mutagenesis (Avedillo
Dı´ez et al., 2011; Boztug et al., 2010).
The investigators in the current study uti-
lized a third generation lentivirus vector
in which expression of the WAS cDNA
was controlled by cis-regulatory elements
of the WAS gene in an attempt to restrict
transgene expression to the target cells
required for phenotypic correction and
potentially reduce enhancer effects in
other lineages. Three patients received
infusion of autologous genetically modi-
fied HSC/Ps after reduced chemotherapy
conditioning to enhance engraftment of
these cells. This treatment resulted in
improved (but not normal) platelet counts
with increased platelet size and reduced
bleeding, allowing the patients to become
platelet-transfusion independent. More-
over, improved immune function and
reduced autoimmune symptoms were
observed.
Both studies performed integration
analyses, which showed improved trans-
duction of HSC/Ps and robust poly-
clonality of the graft, in different blood
lineages. The evaluation of safety is still
early in these trials and therefore relieseptember 5, 2013 ª2013 Elsevier Inc. 263
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Previewsheavily on bioinformatic analysis of inte-
gration sites of the vector. This analysis
monitors changes in the contribution of
molecularly identified progeny of trans-
duced primitive cells over time. The data
reported showno evidence to date of vec-
tor genotoxicity. However, it should be
noted that the leukemias or preleukemia
myelodysplasia in previous trials (Sey-
mour and Thrasher, 2012) only became
evident years after infusion of genetically
altered cells, and an additional safety
concern of the MLD trial is ‘‘pheno-
toxicity,’’ i.e., potential long-term conse-
quences of higher than normal levels of
ARSA protein expression.
The authors make comparisons of the
insertional patterns of the lentiviral vectors
utilized in this study with g-retroviruses
(RVs) utilized inprevioushumangene ther-
apy studies. While these comparisons are
valid, three points should be made. First,
the insertion profile is only part of the rele-
vant differences in these vector systems.
Indeed, lentivirus vectors are attractive
for transduction of HSCs because they
appear to more efficiently transduce non-
actively dividing cells (Naldini et al., 1996).
Second, while statistically significant dif-
ferences do exist in integration prefer-
ences of these different vectors in several
model systems, the biological relevance
of these differences is less clear and in
human trials is yet unknown. For instance,
in striking contrast to insertional mutagen-
esis in the X-linked Severe Combined
Immune Deficiency (SCID-X1) and other264 Cell Stem Cell 13, September 5, 2013 ª2trials, no adverse events have been
reported in the patients treated in several
ADA-SCID trials despite the use of an
RV vector with a similar pattern of viral
integrations (Aiuti et al., 2007). Third, while
the early generation of RVs utilized in
human trials contained the enhancer
elements that were implicated in inser-
tional mutagenesis, newer vectors lack
these sequences. Thus, an interesting
question currently being studied in a sub-
sequent human trial in SCID-X1 (http://
clinicaltrials.gov, NCT01129544) is how
the deletion of the enhancer region of the
RV affects integration-driven clonal skew-
ing in vivo and long-term safety. This com-
parisonwill bemuchmore of an ‘‘apples to
apples’’ comparison of vector safety.
Perhaps of more importance to the
field, particularly in light of the results
from the MLD study, is that gene transfer
technology could now be considered at
least as effective as, and in some cases
even superior to, allogeneic HSC trans-
plantation. In addition to the obvious
advantages that using autologous cells
has over an allogeneic stem cell source
(no need to search for an appropriate
donor, no risk of graft-versus-host
disease), this study demonstrates how
genetically manufactured cells can
perform as ‘‘optimized medicines,’’ both
perceiving the environment they are in
and delivering supraphysiological con-
centrations of functional protein for pro-
longed periods of time into a diseased
microenvironment. One can envision that013 Elsevier Inc.the convergence of this technology with
newer approaches to regenerative medi-
cine (such as somatic cell reprogram-
ming) could yield benefits not even
imagined when gene therapy was first
predicted to revolutionize medicine.
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